Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2026-04-09 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺
Regulatory Filings Classification · 95% confidence The document is a statement and commitment by an independent director candidate for a company's board, detailing qualifications, independence criteria, and legal compliance. It is not a financial report, earnings release, or regulatory filing about financial performance. It is also not an announcement of board changes but a declaration by a candidate. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories.
2026-04-09 Chinese
股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding planned shareholding reduction by certain shareholders of the company. It details the shareholders involved, the number and percentage of shares planned to be reduced, the methods and timing of the reduction, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report attached or referenced as being published. The content fits the description of a Major Shareholding Notification, specifically about changes in significant share ownership levels and planned share reductions by major shareholders.
2026-03-25 Chinese
关于独立董事届满离任的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the departure of an independent director due to term expiration. It details the compliance and impact of this board member change, including references to relevant regulations and company bylaws. There is no financial data, no mention of financial results, or report publication. The content focuses solely on board/management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2026-03-17 Chinese
关于收到8个药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the receipt of 8 drug re-registration approval notices issued by the Sichuan Provincial Drug Administration. It lists the drug names, specifications, approval numbers, and validity periods. The document includes a statement on the impact and risk warning related to these approvals. There is no financial data, no mention of financial results, no management discussion of financial performance, no shareholder voting results, no executive changes, no merger or acquisition activity, and no regulatory certification. The document is a regulatory announcement about drug registration approvals, which is a compliance-related disclosure. It is not a report or financial filing but a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1196 characters), and it is a direct announcement, not a report publication announcement or certification letter. Confidence is high due to clear content and context.
2026-03-17 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds for entrusted financial management. It details the amounts, types, counterparties, and risk controls related to the company's investment in low-risk short-term financial products. The document includes tables of current and past entrusted financial products, their terms, and yields. It is a regulatory disclosure about capital management activities, specifically the use of idle funds for financial products, and does not contain financial statements or earnings data. It is not an annual or interim report, earnings release, or audit report. It is not a report publication announcement since it contains substantive information rather than just announcing a report. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage related to entrusted financial management.
2026-03-17 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds for entrusted financial management. It includes specifics about the amounts, products, expected yields, dates, and risk controls related to the company's investment in low-risk short-term financial products. The document is not a financial report like an annual or interim report, nor is it a regulatory certification or a simple announcement of a report. It is a disclosure about capital usage and investment activities, specifically about entrusted financial management and cash management. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and capital usage. The document length is 3773 characters, which is substantive and contains detailed financial information about the company's capital management activities, not just a brief notice or announcement. Therefore, the classification is CAP with high confidence.
2026-03-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.